PDGFRα depletion attenuates glioblastoma stem cells features by modulation of STAT3, RB1 and multiple oncogenic signals

Platelet derived growth factor receptors (PDGFRs) play an important role in tumor pathogenesis, and they are frequently overexpressed in glioblastoma (GBM). Earlier we have shown a higher protein expression of PDGFR isoforms (α and β) in peritumoral-tissue derived cancer stem cells (p-CSC) than in tumor core (c-CSC) of several GBM affected patients. In the current study, in order to assess the activity of PDGFRα/PDGF-AA signaling axis, we performed time course experiments to monitor the effects of exogenous PDGF-AA on the expression of downstream target genes in c-CSC vs p-CSC. Interestingly, in p-CSC we detected the upregulation of Y705-phosphorylated Stat3, concurrent with a decrement of Rb1 protein in its active state, within minutes of PDGF-AA addition. This finding prompted us to elucidate the role of PDGFRα in self-renewal, invasion and differentiation in p-CSC by using short hairpin RNA depletion of PDGFRα expression. Notably, in PDGFRα-depleted cells, protein analysis revealed attenuation of stemness-related and glial markers expression, alongside early activation of the neuronal marker MAP2a/b that correlated with the induction of tumor suppressor Rb1. The in vitro reduction of the invasive capacity of PDGFRα-depleted CSC as compared to parental cells correlated with the downmodulation of markers of epithelial-mesenchymal transition phenotype and angiogenesis. Surprisingly, we observed the induction of anti-apoptotic proteins and compensatory oncogenic signals such as EDN1, EDNRB, PRKCB1, PDGF-C and PDGF-D. To conclude, we hypothesize that the newly discovered PDGFRα/Stat3/Rb1 regulatory axis might represent a potential therapeutic target for GBM treatment.

[1]  D. Figarella-Branger,et al.  A Positive Feed-forward Loop Associating EGR1 and PDGFA Promotes Proliferation and Self-renewal in Glioblastoma Stem Cells* , 2016, The Journal of Biological Chemistry.

[2]  R. Bernards,et al.  Targeting the RB-E2F pathway in breast cancer , 2016, Oncogene.

[3]  K. McDonald,et al.  CDK4/6 Inhibitor PD0332991 in Glioblastoma Treatment: Does It Have a Future? , 2015, Front. Oncol..

[4]  P. Canoll,et al.  TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo , 2015, Oncotarget.

[5]  Lihua Huang,et al.  Mechanisms of resistance to EGFR tyrosine kinase inhibitors , 2015, Acta pharmaceutica Sinica. B.

[6]  K. Aldape,et al.  Macitentan, a Dual Endothelin Receptor Antagonist, in Combination with Temozolomide Leads to Glioblastoma Regression and Long-term Survival in Mice , 2015, Clinical Cancer Research.

[7]  A. Giordano,et al.  RB1 dual role in proliferation and apoptosis: Cell fate control and implications for cancer therapy , 2015, Oncotarget.

[8]  L. Qin,et al.  WNT5A promotes stemness characteristics in nasopharyngeal carcinoma cells leading to metastasis and tumorigenesis , 2015, Oncotarget.

[9]  PDGF receptor alpha inhibition induces apoptosis in glioblastoma cancer stem cells refractory to anti-Notch and anti-EGFR treatment , 2014, Molecular Cancer.

[10]  C. Heldin,et al.  Targeting the PDGF signaling pathway in tumor treatment , 2013, Cell Communication and Signaling.

[11]  B. Zhou,et al.  The Role of Snail in EMT and Tumorigenesis. , 2013, Current cancer drug targets.

[12]  F. Spinella,et al.  Endothelin 1 in cancer: biological implications and therapeutic opportunities , 2013, Nature Reviews Cancer.

[13]  Elgene Lim,et al.  Protein kinase C α is a central signaling node and therapeutic target for breast cancer stem cells. , 2013, Cancer cell.

[14]  Milena B. Furtado,et al.  Retinoblastoma protein regulates the crosstalk between autophagy and apoptosis, and favors glioblastoma resistance to etoposide , 2013, Cell Death and Disease.

[15]  Y. Nakanishi,et al.  Serum protein kinase Cα as a diagnostic biomarker of cancers. , 2013, Cancer biomarkers : section A of Disease markers.

[16]  J. Balça-Silva,et al.  PKC signaling in glioblastoma , 2013, Cancer biology & therapy.

[17]  Isabelle Salmon,et al.  A Simplified Approach for the Molecular Classification of Glioblastomas , 2012, PloS one.

[18]  G. Konopka,et al.  STAT3-iNOS Signaling Mediates EGFRvIII-Induced Glial Proliferation and Transformation , 2012, The Journal of Neuroscience.

[19]  Qiulian Wu,et al.  Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity. , 2012, Genes & development.

[20]  A. Heerschap,et al.  Effects of targeting the VEGF and PDGF pathways in diffuse orthotopic glioma models , 2011, The Journal of pathology.

[21]  Jiankai Xu,et al.  Selective inhibition of PDGFR by imatinib elicits the sustained activation of ERK and downstream receptor signaling in malignant glioma cells. , 2011, International journal of oncology.

[22]  A. Satelli,et al.  Vimentin as a potential molecular target in cancer therapy Or Vimentin , an overview and its potential as a molecular target for cancer therapy , 2011 .

[23]  S. Nelson,et al.  Autocrine endothelin-3 / endothelin receptor B signaling maintains cellular and molecular properties of tumorigenic glioblastoma stem cells , 2011 .

[24]  Chih-Chiang Chien,et al.  12‐O‐tetradecanoylphorbol‐13‐acetate‐induced invasion/migration of glioblastoma cells through activating PKCα/ERK/NF‐κB‐dependent MMP‐9 expression , 2010, Journal of cellular physiology.

[25]  A. Falini,et al.  Cancer esearch cular and Cellular Pathobiology ermal Growth Factor Receptor Expression Identifies ctionally and Molecularly Distinct Tumor-Initiating Cells uman Glioblastoma Multiforme and Is Required R Gliomagenesis , 2010 .

[26]  Richard Beyer,et al.  TWIST1 promotes invasion through mesenchymal change in human glioblastoma , 2010, Molecular Cancer.

[27]  M. Prados,et al.  Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. , 2010, Cancer research.

[28]  K. Nakashiro,et al.  Conditional deletion of Stat3 promotes neurogenesis and inhibits astrogliogenesis in neural stem cells. , 2010, Biochemical and biophysical research communications.

[29]  W. Mason,et al.  Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  C. Brennan,et al.  Glioblastoma Subclasses Can Be Defined by Activity among Signal Transduction Pathways and Associated Genomic Alterations , 2009, PloS one.

[31]  B. Cochran,et al.  STAT3 Is Required for Proliferation and Maintenance of Multipotency in Glioblastoma Stem Cells , 2009, Stem cells.

[32]  A. Bonni,et al.  STAT3 regulation of glioblastoma pathogenesis. , 2009, Current molecular medicine.

[33]  G. Maira,et al.  Distinct pools of cancer stem-like cells coexist within human glioblastomas and display different tumorigenicity and independent genomic evolution , 2009, Oncogene.

[34]  Rakesh K. Jain,et al.  PDGF-C Induces Maturation of Blood Vessels in a Model of Glioblastoma and Attenuates the Response to Anti-VEGF Treatment , 2009, PloS one.

[35]  Leigh Zawel,et al.  Resistance of human glioblastoma multiforme cells to growth factor inhibitors is overcome by blockade of inhibitor of apoptosis proteins. , 2008, The Journal of clinical investigation.

[36]  J. Rich,et al.  Antiangiogenic therapy in malignant glioma: promise and challenge. , 2007, Current pharmaceutical design.

[37]  R. Herbst,et al.  Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  E. Holland,et al.  Platelet-derived growth factor (PDGF) and glial tumorigenesis. , 2006, Cancer letters.

[39]  G. Pilkington,et al.  Cancer stem cells in the mammalian central nervous system , 2005, Cell proliferation.

[40]  M. Israel,et al.  Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. , 2002, Cancer research.

[41]  Olav Haraldseth,et al.  NG2 proteoglycan promotes angiogenesis‐dependent tumor growth in the central nervous system by sequestering angiostatin , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[42]  Yuji Saito,et al.  Receptor Heterodimerization: Essential Mechanism for Platelet-Derived Growth Factor-Induced Epidermal Growth Factor Receptor Transactivation , 2001, Molecular and Cellular Biology.

[43]  Yasuhiro Yonekawa,et al.  Promoter Hypermethylation of the RB1 Gene in Glioblastomas , 2001, Laboratory Investigation.

[44]  K. Ichimura,et al.  Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. , 2000, Cancer research.

[45]  J. Harbour,et al.  Cdk Phosphorylation Triggers Sequential Intramolecular Interactions that Progressively Block Rb Functions as Cells Move through G1 , 1999, Cell.

[46]  M. Greenberg,et al.  Regulation of gliogenesis in the central nervous system by the JAK-STAT signaling pathway. , 1997, Science.

[47]  V P Collins,et al.  Human glioblastomas with no alterations of the CDKN2A (p16INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. , 1996, Oncogene.

[48]  C. Heldin,et al.  Interaction between NG2 proteoglycan and PDGF α‐receptor on O2A progenitor cells is required for optimal response to PDGF , 1996, Journal of neuroscience research.

[49]  M. Pagano,et al.  Cyclin D1 is a nuclear protein required for cell cycle progression in G1. , 1993, Genes & development.

[50]  E. Oldfield,et al.  Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. , 1992, Cancer research.

[51]  S. Finkelstein,et al.  Expression pattern of alpha-protein kinase C in human astrocytomas indicates a role in malignant progression. , 1992, Cancer research.

[52]  A. Fields,et al.  Protein kinase C isoforms in human glioblastoma cells , 1992, Glia.

[53]  W. Birchmeier,et al.  E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells , 1991, The Journal of cell biology.